GO
Loading...

GlaxoSmithKline PLC

More

  • WHO: Ebola vaccine trials in W. Africa in January Tuesday, 21 Oct 2014 | 7:19 AM ET

    GENEVA— Tens of thousands of doses of experimental Ebola vaccines could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe, a top World Health Organization official said Tuesday. The Ebola outbreak in West Africa has already killed over 4,500 people, mostly in Liberia, Guinea and Sierra Leone, since it emerged 10...

  • LONDON, Oct 14- GlaxoSmithKline is seeking binding bids by next month for a range of older drugs worth more than $3 billion, which it is likely to sell by geographical region, according to people with direct knowledge of the process. Britain's biggest drug maker is looking to divest the mature products in a bid to improve its growth profile and wants to dispose of...

  • CDC must 'rethink' its approach to Ebola: Official Monday, 13 Oct 2014 | 1:26 PM ET
    A man dressed in protective hazmat clothing treats the sidewalk in front of an apartment where a second person diagnosed with the Ebola virus resides on October 12, in Dallas, Texas

    "We have to rethink the way we address Ebola infection control because even a single infection is unacceptable," said Dr. Thomas Frieden.

  • Cramer: Activists are picking on the wrong chiefs Thursday, 9 Oct 2014 | 6:25 PM ET
    Jim Cramer on Mad Money.

    Jim Cramer takes on activist calls to CEOs strong performing companies, and suggests they realign their attention

  • 'Ebola.com' can be yours for $150,000 Thursday, 9 Oct 2014 | 9:53 AM ET
    The Cleaning Guys hazmat cleanup company are seen here as they sanitize the apartment where Ebola patient Thomas Eric Duncan was staying before being admitted to a hospital in Dallas.

    It's not unusual for big pharmaceutical companies to hold domains for major diseases on the Internet. But who would want to own Ebola.com?

  • Why we haven't cured Ebola yet Wednesday, 8 Oct 2014 | 2:41 PM ET
    U.S. Navy microbiologist Lt. Jimmy Regeimbal prepares to test blood samples for Ebola at the U.S. Navy mobile laboratory on Oct. 5, 2014 near Gbarnga, Liberia.

    Several drug companies are moving to test vaccines and drug treatments for Ebola, but their full effect might not be felt until the next outbreak.

  • Early movers: JCP, COST, CMI, GRUB, KRFT, YUM Wednesday, 8 Oct 2014 | 7:48 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • GSK investigating corruption allegations in UAE Wednesday, 8 Oct 2014 | 1:17 AM ET
    GlaxoSmithKline headquarters in London.

    GlaxoSmithKline, which was slapped with a record fine for corruption in China, said it was looking into allegations of corruption in UAE.

  • Fast-tracking an Ebola vaccine may prove too slow Tuesday, 7 Oct 2014 | 12:16 PM ET
    Ebola virus

    GlaxoSmithKline said it's speeding up trials and scaling production of an Ebola vaccine, but does not expect to be able to make it in mass quantities for 12 to 18 months.

  • While Lilly's shares hardly budged on the news, the ADRs of Israel- based XTL Biopharmaceuticals Inc, which is developing its own lupus treatment, nearly tripled to $5.00. About 1.5 million people in the United States are estimated to suffer from lupus, according to the U.S. Centers of Disease Control and Prevention. The U.S. Food and Drug Administration approved...

  • Ebola vaccine: Why it's taking so long to make one Thursday, 2 Oct 2014 | 10:46 AM ET
    A health worker helps a doctor to fix his protective suit, on October 1, 2014 at MSF's (Doctors Without Borders) Ebola treatment center in Monrovia. Liberia.

    Efforts to develop an Ebola vaccine have been in the works for some time. But experts say it's unlikely to see one available anytime soon.

  • NEW YORK, Oct. 1- Two tiny companies are preparing to challenge some of the world's largest drug makers in the battle for dominance in the $3 billion global market for influenza vaccines, armed with little more than tiny tobacco plants.

  • *Roche set to compete with established GSK combination. *Shares in Roche's biotech partner Exelixis jump 20 pct. MADRID, Sept 29- Rival two-pill combinations for melanoma from Roche and GlaxoSmithKline had similarly good results in separate clinical trials, leaving doctors with little to choose between the two skin cancer courses.

  • GSK appoints RBS's Hampton as next chairman Thursday, 25 Sep 2014 | 3:45 AM ET

    GlaxoSmithKline said on Thursday it had chosen Philip Hampton, who currently chairs Royal Bank of Scotland, as its next chairman.

  • LONDON, Sept 25- GlaxoSmithKline said on Thursday it had chosen Philip Hampton, who currently chairs Royal Bank of Scotland, as its next chairman. GSK was hit last week by a record $489 million fine in China for bribing doctors and has warned on profits in 2014 due to weak sales of its core respiratory drugs.

  • GSK chooses Philip Hampton as next chairman Thursday, 25 Sep 2014 | 3:10 AM ET

    LONDON, Sept 25- GlaxoSmithKline said on Thursday it had chosen Philip Hampton, who currently chairs Royal Bank of Scotland, as its next chairman.

  • Inovio to start human trials of Ebola vaccine Wednesday, 24 Sep 2014 | 11:28 AM ET

    Sept 24- Vaccine developer Inovio Pharmaceuticals Inc said the company and its partner GeneOne Life Science Inc will start testing its experimental Ebola vaccine in humans in the first half of 2015.. Two other vaccine candidates in development are from GlaxoSmithKline Plc and NewLink Genetics Corp..

  • WASHINGTON/ SHANGHAI, Sept 23- U.S. regulators will pay a record $30 million bounty to an anonymous whistleblower outside the United States, underlining the growing reach of the country's watchdogs and creating a headache for global firms in fast-growing emerging markets.

  • LONDON, Sept 22- GlaxoSmithKline may have closed one chapter in a saga of corruption allegations by accepting a $489 million fine in China, but the drugmaker has its work cut out to win back sceptical investors.

  • Early movers: ORCL, AAPL, BABA, HD, WMT, GSK & more Friday, 19 Sep 2014 | 7:41 AM ET
    Traders work on the floor of the New York Stock Exchange in New York.

    Some of the names on the move ahead of the open.